Primary Membranous Nephropathy (PMN) Emerging Therapy and TPP Insights

Thelansis’s “Primary Membranous Nephropathy (PMN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Primary Membranous Nephropathy (PMN) Overview

Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults, characterised by immune complex deposition along the glomerular basement membrane subepithelial surface, driven predominantly by autoantibodies — most critically anti-PLA2R antibodies, present in approximately 70-80% of cases — targeting podocyte antigens, activating complement, and disrupting the glomerular filtration barrier. Anti-THSD7A antibodies account for a further subset, with additional novel antigenic targets increasingly recognised. Patients present with insidious-onset nephrotic syndrome — heavy proteinuria, hypoalbuminaemia, peripheral oedema, and hyperlipidaemia — with significant risks of thromboembolic complications, particularly renal vein thrombosis, and progressive chronic kidney disease. Diagnosis integrates renal biopsy demonstrating characteristic subepithelial deposits on electron microscopy, with anti-PLA2R antibody titres serving as both diagnostic and disease activity monitoring biomarkers. Spontaneous remission occurs in approximately one-third of patients, justifying an initial conservative approach with optimised renin-angiotensin-aldosterone system blockade, lipid management, and anticoagulation where indicated. Immunosuppressive therapy — historically cyclophosphamide-based Ponticelli regimen or calcineurin inhibitors — is reserved for persistent or high-risk proteinuria. Rituximab, targeting CD20-positive B-cells to suppress autoantibody production, has emerged as the preferred first-line immunosuppressive strategy given favourable efficacy and tolerability. Prognosis is variable; regular proteinuria and anti-PLA2R titre monitoring, nephrology surveillance, and patient-centred cardiovascular and renal risk optimisation underpin long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)